Resistant Hypertension
- PMID: 26935512
- DOI: 10.17219/acem/58998
Resistant Hypertension
Abstract
Resistant hypertension is a severe medical condition which is estimated to appear in 9-18% of hypertensive patients. Due to higher cardiovascular risk, this disorder requires special diagnosis and treatment. The heterogeneous etiology, risk factors and comorbidities of resistant hypertension stand in need of sophisticated evaluation to confirm the diagnosis and select the best therapeutic options, which should consider lifestyle modifications as well as pharmacological and interventional treatment. After having excluded pseudohypertension, inappropriate blood pressure measurement and control as well as the white coat effect, suspicion of resistant hypertension requires an analysis of drugs which the hypertensive patient is treated with. According to one definition - ineffective treatment with 3 or more antihypertensive drugs including diuretics makes it possible to diagnose resistant hypertension. A multidrug therapy including angiotensin - converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers, diuretics, long-acting calcium channel blockers and mineralocorticoid receptor antagonists has been demonstrated to be effective in resistant hypertension treatment. Nevertheless, optional, innovative therapies, e.g. a renal denervation or baroreflex activation, may create a novel pathway of blood pressure lowering procedures. The right diagnosis of this disease needs to eliminate the secondary causes of resistant hypertension e.g. obstructive sleep apnea, atherosclerosis and renal or hormonal disorders. This paper briefly summarizes the identification of the causes of resistant hypertension and therapeutic strategies, which may contribute to the proper diagnosis and an improvement of the long term management of resistant hypertension.
Similar articles
-
Emerging concepts for patients with treatment-resistant hypertension.Trends Cardiovasc Med. 2016 Nov;26(8):700-706. doi: 10.1016/j.tcm.2016.05.004. Epub 2016 May 17. Trends Cardiovasc Med. 2016. PMID: 27381561 Free PMC article. Review.
-
New therapies for arterial hypertension.Panminerva Med. 2016 Mar;58(1):34-47. Epub 2016 Jan 5. Panminerva Med. 2016. PMID: 26730462 Review.
-
New approaches in the treatment of hypertension.Circ Res. 2015 Mar 13;116(6):1074-95. doi: 10.1161/CIRCRESAHA.116.303603. Circ Res. 2015. PMID: 25767291 Review.
-
Baroreceptor stimulation for resistant hypertension: first implantation in France and literature review.Arch Cardiovasc Dis. 2014 Dec;107(12):690-6. doi: 10.1016/j.acvd.2014.08.002. Epub 2014 Oct 16. Arch Cardiovasc Dis. 2014. PMID: 25445751 Review.
-
Resistant hypertension: a practical clinical approach.J Hum Hypertens. 2013 Nov;27(11):657-62. doi: 10.1038/jhh.2013.34. Epub 2013 May 2. J Hum Hypertens. 2013. PMID: 23636008 Review.
Cited by
-
Vasorelaxant and Blood Pressure-Lowering Effects of Cnidium monnieri Fruit Ethanol Extract in Sprague Dawley and Spontaneously Hypertensive Rats.Int J Mol Sci. 2024 Apr 11;25(8):4223. doi: 10.3390/ijms25084223. Int J Mol Sci. 2024. PMID: 38673809 Free PMC article.
-
Renal TLR-7/TNF-α pathway as a potential female-specific mechanism in the pathogenesis of autoimmune-induced hypertension.Am J Physiol Heart Circ Physiol. 2022 Dec 1;323(6):H1331-H1342. doi: 10.1152/ajpheart.00286.2022. Epub 2022 Nov 11. Am J Physiol Heart Circ Physiol. 2022. PMID: 36367687 Free PMC article.
-
Fighting Oxidative Stress with Sulfur: Hydrogen Sulfide in the Renal and Cardiovascular Systems.Antioxidants (Basel). 2021 Mar 2;10(3):373. doi: 10.3390/antiox10030373. Antioxidants (Basel). 2021. PMID: 33801446 Free PMC article. Review.
-
Sodium-Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome.Antioxidants (Basel). 2024 Jun 26;13(7):768. doi: 10.3390/antiox13070768. Antioxidants (Basel). 2024. PMID: 39061837 Free PMC article. Review.
-
Renal Epithelial Mitochondria: Implications for Hypertensive Kidney Disease.Compr Physiol. 2023 Dec 29;14(1):5225-5242. doi: 10.1002/cphy.c220033. Compr Physiol. 2023. PMID: 38158371 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical